This collaboration will combine Vipergen’s high-fidelity DEL screening technologies and Aurigene Pharmaceutical Services’ existing small molecule drug discovery capabilities to enhance end-to-end discovery solutions with advanced hit screening
Companies will co-market and introduce DEL screening technologies to global customers as an integrated drug discovery service or a standalone service
With a focus on novel chemical diversity and drug likeliness, companies will also co-develop new DELs to strengthen their services
Ref: Aurigene | Image: Aurigene
Related News:- Dr. Reddy’s Subsidiary Aurigene Stops Clinical Development of AUR-101 for the Treatment of Psoriasis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
